Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera

New England Journal of Medicine

Volumn 338, Issue 9, 1998, Pages 572-580

  Moliterno, Alison R ^a   David Hankins, W ^a   Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE RECEPTOR; THROMBOPOIETIN;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; GENE EXPRESSION; HEMATOPOIESIS; HEMOCHROMATOSIS; HUMAN; IRON DEFICIENCY ANEMIA; MYELOFIBROSIS; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; THROMBOCYTOSIS;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MEGAKARYOCYTES; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PHOSPHORYLATION; POLYCYTHEMIA VERA; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THROMBIN; THROMBOPOIETIN; TYROSINE;

EID: 2642609475     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802263380903     Document Type: Article

References (44)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-6.
2. Jacobson RJ, Sale A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189 94.
3. Fialkow PJ, Jacobson RJ, Singer JW, Sacher RA, McGuffin RW, Neefe JR. Philadelphia chromosome (Ph1)-negativc chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell. Blood 1980;56:70-3.
4. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-9.
5. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382.
6. Cashman J, Henkelman D, Humphries K, Eaves C, Eaves A. Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny. Blood 1983;61:876-84.
7. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994;83:99-112.
8. de Wolf JT, Beentjes JA, Esselink MT, et al. In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. Exp Hematol 1989;17:981-3.
9. Dai CH, Krantz SB, Dessypris EN, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80: 891-9.
10. Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994;86:12-21.
11. Emanuel PD, Eaves CJ, Broudy VC, et al. Familial and congenital polycythemia in three unrelated families. Blood 1992;79:3019-30.
12. Means RT Jr, Krantz SB, Sawyer ST, Gilbert HS. Erythropoietin receptors in polycythemia vera. J Clin Invest 1989;84:1340-4.
13. Le Couedic JP, Mitjavila MT, Villeval JL, et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 1996;87:1502-11.
14. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994;88:794-802.
15. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993;90:4495-9.
16. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995;86:15-22.
17. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-31.
18. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87:4544-51.
19. Carver-Moore K, Broxmcyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996;88:803-8.
20. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995;86:4025-33.
21. Cocault L, Bouscary D, Le Bousse Kerdiles C, et al. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood 1996;88:1656-65.
22. Wendling F, Varlet P, Charon M, Tambourin E MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 1986;149:242-6.
23. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990;63:1137-47
24. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
25. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR, Abnormalities of platelet function in patients with polycythemia vera. Cancer Res 1973;33:2683-7
26. Raman BK, Van Slyck EJ, Riddle J, Sawdyk MA, Abraham JP, Saeed SM. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 1989;91:647-55.
27. Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl Med 1982;306:381-6.
28. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23: 132-43.
29. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology: basic principles and practice. 2nd ed. New York: Churchill Livingstone, 1995.
30. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
31. Marsh JCW, Gibson FM, Prue RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996;95:605-10.
32. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-5.
33. Vignon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992;89:5640-4.
34. Tortolani PJ, Johnston JA, Bacon CM, et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 1995;85:3444-51.
35. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 1995;270:4979-82.
36. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52.
37. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995;86:23-7.
38. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996;87:439-46.
39. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfaninduced thrombocytopenia in the rabbit. Blood 1995;85:2720-30.
40. Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-71.
41. Oda A, Miyakawa Y, Druker BJ, et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996;88:4304-13.
42. Cooper B, Ahern D. Characterization of the platelet prostaglandin D2 receptor: loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest 1979;64:586-90.
43. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated with a deficiency of platelet α-adrcncrgic receptors. N Engl J Med 1978; 299:505-9.
44. Damen JE, Krystal G. Early events in erythropoietin-induced signaling. Exp Hematol 1996;24:1455-9.